Summary

Overview
The global non-small cell lung cancer therapeutics market reached US$ 21.33 billion in 2024 and is expected to reach US$ 64.92 billion by 2033, growing at a CAGR of 11.75% during the forecast period 2025-2033.
Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer of all lung cancer cases. It encompasses various subtypes, primarily adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma, the most common subtype, often arises in the outer regions of the lungs and can occur in non-smokers.
The treatment landscape for NSCLC includes several therapeutic options tailored to the disease's stage and characteristics. For patients with unresectable disease, radiation therapy may be employed to control local disease. Chemotherapy remains a cornerstone for advanced stages, often used in conjunction with surgery as neoadjuvant or adjuvant therapy.
Recent advancements have led to the emergence of targeted therapies that focus on specific genetic mutations within tumor cells, providing more personalized treatment options. Additionally, immunotherapy has revolutionized NSCLC treatment by harnessing the body's immune system to fight cancer cells, offering significant survival benefits for many patients.
Market Dynamics: Drivers & Restraints
Advancements in Research and Development
Advancements in research and development are expected to significantly drive the non-small cell lung cancer (NSCLC) therapeutics market by fostering innovation and enhancing treatment efficacy. Continuous investment in R&D has led to the development of novel therapies, particularly in targeted therapy and immunotherapy, which have shown promising results in improving patient outcomes.
Additionally, the increasing studies of cancer biology have facilitated the design of combination therapies that leverage multiple mechanisms of action, further improving therapeutic efficacy. For instance, in December 2022, GSK plc announced results from the PERLA phase II clinical trial investigating dostarlimab in combination with chemotherapy versus pembrolizumab in combination with chemotherapy as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
The growing pipeline of new drugs and the emergence of personalized medicine approaches are also contributing to market expansion, as they cater to the unique genetic profiles of patients. The development of innovative solutions with advanced research is contributing to the market growth. For instance, in December 2024, Datopotamab deruxtecan (Dato-DXd) was granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
Furthermore, increased funding from both the government and private sectors for cancer research is promoting innovation, leading to the introduction of advanced treatment options that are expected to meet the rising demand for effective NSCLC therapies. As a result, these advancements are likely to enhance treatment accessibility and improve overall survival rates, thereby propelling growth in the NSCLC therapeutics market.
High Costs of Treatment
The high costs of treating non-small cell lung cancer (NSCLC) are expected to impede the growth of the non-small cell lung cancer therapeutics market significantly. This financial burden often results in lower treatment adherence or even the choice to skip therapy entirely, especially among low- and middle-income populations.
Additionally, the absence of price competition among new drugs worsens the situation, as prices keep increasing without any corresponding improvements in patient outcomes. As a result, these affordability issues affect individual patients and put pressure on healthcare systems, which could lead to decreased investment in new drug development and restrict market growth.
Segment Analysis
The global non-small cell lung cancer therapeutics market is segmented based on type, treatment, end-user, and region.
Treatment:
Targeted therapy segment is expected to dominate the global non-small cell lung cancer therapeutics market share
Targeted therapy segment is expected to dominate the non-small cell lung cancer therapeutics market. This dominance is attributed to several factors. Targeted therapies specifically address genetic mutations and molecular pathways involved in cancer growth, which can lead to improved patient outcomes and fewer side effects compared to traditional chemotherapy.
Additionally, advancements in research and the development of new targeted agents continue to enhance their effectiveness, making them a preferred choice for treating advanced NSCLC. Companies are developing advanced targeted therapies. For instance, in February 2024, Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088, a targetted drug intended for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations who have previously received systemic therapy.
While chemotherapy remains widely used, especially in developing regions, the trend is shifting towards more personalized and effective treatment modalities like targeted therapy, which is expected to drive further growth in the NSCLC therapeutics market.
Geographical Analysis
North America is expected to hold a significant position in the global non-small cell lung cancer therapeutics market share
North America is expected to dominate the non-small cell lung cancer (NSCLC) therapeutics market due to several key factors. The dominance is driven by a robust healthcare infrastructure, advanced medical technologies, and the presence of major pharmaceutical companies actively developing innovative therapies. The companies are receiving approvals for their innovative solutions which are contributing to the market growth. For instance, In August 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) granted approval for its combination treatment of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) exhibiting epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as identified by an FDA-approved test.
Companies in the region are increasingly investing in developing innovative therapeutics to address the disease. For instance, in March 2024, Merck announced that the Phase 3 KEYLYNK-006 trial assessing KEYTRUDA, Merck's anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not achieve its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
Increased awareness regarding early diagnosis and treatment options has further contributed to market growth, as more patients seek timely interventions. The U.S. specifically plays a pivotal role in this landscape due to high smoking rates and air pollution contributing to lung cancer prevalence. With ongoing investments in research and development, North America is poised to maintain its leadership position in the NSCLC therapeutics market for the foreseeable future.
Competitive Landscape
The major global players in the non-small cell lung cancer therapeutics market include F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca and Johnson & Johnson Services, Inc. among others.
Key Developments
• In August 2024, AstraZeneca's Imfinzi (durvalumab) received approval in the United States for use in combination with chemotherapy to treat adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
• In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation, as identified by an FDA-approved test. This approval provides a new personalized treatment option for patients with this specific mutation in their cancer.
• In August 2023, Eli Lilly and Company announced the topline results from the LIBRETTO-431 study, which evaluated Retevmo (selpercatinib) against platinum-based chemotherapy plus pemetrexed as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Non-Small Cell Lung Cancer Therapeutics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

• Supply Chain: Distribution and Supply Chain Managers.

• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

• Academic & Research: Academic Institutions.

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Advancements in Research and Development
4.1.2. Restraints
4.1.2.1. High Costs of Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Type
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Adenocarcinoma*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Squamous Cell Carcinoma
6.4. Large Cell Carcinoma
6.5. Adenosquamous Carcinoma
6.6. Sarcomatoid Carcinoma
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Radiation Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chemotherapy
7.4. Targeted Therapy
7.5. Immunotherapy
7.6. Laser Therapy
7.7. Photodynamic Therapy (PDT)
7.8. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cancer Centers
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. F. Hoffmann-La Roche Ltd*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. Mylan N.V.
11.3. Teva Pharmaceutical Industries Ltd.
11.4. Pfizer Inc.
11.5. Novartis AG
11.6. Bayer AG
11.7. Eli Lilly and Company
11.8. Merck & Co., Inc.
11.9. AstraZeneca
11.10. Johnson & Johnson Services, Inc.
* Similar data will be provided for each market player.
Emerging Market Players
11.11. Processa Pharmaceuticals, Inc.*
11.11.1. Pipeline Products Description
11.11.2. Product Key Performance Indicators (KPIs)
11.11.3. Key Activities
11.11.4. Market Entry Timelines
11.11.5. Product Penetration Rate
11.11.6. Sales Estimation and Projections
11.12. Vanda Pharmaceuticals Inc.
11.13. Renexxion Ireland Limited
11.14. Aclipse Therapeutics
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us